Your Health, We Care
Release date: 2026-01-26 15:14:00 Recommended: 16
Lorlatinib is a targeted therapy indicated for the treatment of specific ALK or ROS1-positive advanced non-small cell lung cancer (NSCLC). It must be administered strictly in accordance with the doctor’s instructions.
During treatment, attention should be paid to dose adjustment, administration on an empty stomach, regular monitoring of clinical indicators, management of drug interactions and adverse reactions, and avoidance of specific foods (e.g., grapefruit).
Strictly follow the doctor’s advice: The dosage should be adjusted based on disease status, adverse reactions and individual differences. Do not increase, decrease or discontinue the medication without authorization.
Administration on an empty stomach: It is recommended to take the medicine 1 hour before meals or 2 hours after meals to avoid the impact of food on drug absorption.
Missed dose management: If a dose is missed and less than 4 hours have elapsed, take the missed dose as soon as possible. If more than 4 hours have passed, skip the missed dose and take the next scheduled dose as planned. Do not take a double dose.
Avoid grapefruit and its products: Grapefruit may inhibit drug metabolism, thereby increasing plasma drug concentration and the risk of toxicity.
Use caution with dietary supplements containing St. John’s Wort: Such supplements may reduce the efficacy of lorlatinib.
Regular examinations: These include liver function tests (every 2–4 weeks), complete blood count (to monitor for anemia or infection), electrocardiogram (to monitor the risk of QT interval prolongation) and imaging assessments (e.g., CT/MRI).
Monitor for neurological symptoms: Symptoms such as headache, visual changes and cognitive impairment may be associated with cerebral edema or neurotoxicity, and prompt medical attention is required.
Common reactions: Hypercholesterolemia/hypertriglyceridemia, edema, fatigue, etc. Symptomatic treatment (e.g., lipid-lowering drugs) should be administered as appropriate.
Severe reactions: Dyspnea, chest pain, cardiac arrhythmias or severe liver injury (jaundice, abdominal pain) require immediate drug discontinuation and medical intervention.
Inform the doctor of all medications being taken: This includes prescription drugs, over-the-counter drugs and traditional Chinese medicines. Special care should be taken to avoid concurrent use with strong CYP3A inducers/inhibitors (e.g., rifampicin, clarithromycin).
Proton pump inhibitors (e.g., omeprazole): May reduce the efficacy of lorlatinib. Administration intervals should be adjusted or alternative medications considered.
Contraindicated in pregnant women: May cause fetal malformation. Strict contraception is required during treatment and for at least 6 months after discontinuation.
Lactating women: It is recommended to discontinue either the drug or breastfeeding.
Patients with hepatic or renal impairment: Dosage adjustment is required, and relevant clinical indicators should be closely monitored.
Store in a dry place at 20–25℃, protected from light. Ensure the medication is out of the reach of children.
Note: Lorlatinib is a prescription drug, and the specific treatment regimen must be determined based on clinical evaluation. In case of any abnormal symptoms during treatment, contact the attending physician promptly to adjust the treatment strategy.
